Evidence map›Paper›PMID 30078111›Full record

Trial reportChild psychiatry and human development2019

N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.

Ovsanna Leyfer, Aubrey Carpenter, Donna Pincus

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Child psychiatry and human development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ovsanna LeyferDepartment of Psychological and Brain Sciences, Center for Anxiety and Related Disorders, Boston University, Boston, MA, USA. oleyfer@bu.edu.ORCID 0000-0003-1575-6655
Aubrey CarpenterMassachusetts General Hospital, Boston, MA, USA.
Donna PincusDepartment of Psychological and Brain Sciences, Center for Anxiety and Related Disorders, Boston University, Boston, MA, USA.
Boston University · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Panic disorder (PD) can result in significant functional impairment. Studies of cognitive behavioral therapy (CBT) for PD have demonstrated response rates ranging between 38 and 65%. D-cycloserine (DCS), a partial NMDA agonist, may enhance the effects of exposure-based therapy for PD in adults; however, no studies have examined its effect in adolescents with PD. This study examined the feasibility and acceptability of the use of DCS to augment intensive CBT for PD in adolescents. Twenty-four adolescents (ages 12-17) participated in this randomized, double-blinded, placebo-controlled trial, to compare CBT + DCS to CBT + placebo. The results demonstrated the feasibility and acceptability of the treatment to participants. No significant differences were found between the two groups, but both groups showed significant improvement. This is the first investigation of DCS in the treatment of PD in adolescents and it provides initial support for a more extensive study of DCS augmentation of CBT among adolescents with PD.

Indexed as

Panic DisorderAdolescentAdultCognitive Behavioral TherapyCombined Modality TherapyCycloserineDouble-Blind MethodFearFemaleHumansImplosive TherapyMaleN-MethylaspartateParentsPsychotropic DrugsTreatment OutcomeCycloserineN-MethylaspartatePsychotropic DrugsAdolescentsAnxietyCognitive-behavioral therapyD-CycloserineOutcomePanic disorder

Identifiers

PMID30078111
OpenAlexW2887295117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.